Renaissance Technologies LLC lowered its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 6.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 14,961,089 shares of the biotechnology company’s stock after selling 1,069,755 shares during the period. Renaissance Technologies LLC owned about […]
Exelixis, Inc. (NASDAQ:EXEL – Get Rating) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among analysts that have […]
Commerce Bank boosted its position in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 275,990 shares of the biotechnology company’s stock after purchasing an additional 15,400 shares during the quarter. Commerce Bank owned about 0.09% […]
Exelixis, Inc. (NASDAQ:EXEL – Get Rating) was the recipient of a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 6,100,000 shares, a decrease of 9.9% from the April 15th total of 6,770,000 shares. Based on an average daily trading volume, of 3,100,000 shares, the […]
Polaris Capital Management LLC increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 85.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,900 shares of the biotechnology company’s stock after buying an additional 36,900 shares during […]